# A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

> **NCT03642340** · — · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 3000 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03642340
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-15
- **Primary completion:** 2023-05-14
- **Final completion:** 2023-08-15
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642340, "A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03642340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*